alovudine Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Alovudine (fluorothymidine) is an antiviral agent which was being developed by Medivir. It was discontinued after a Phase II trial in 2005 due to toxicity. It is a DNA polymerase inhibitor.   Wikipedia

Chemistry

  • SMILES: CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O
  • InChIKey: UXCAQJAQSWSNPQ-XLPZGREQSA-N
  • Mol. Mass: 244.22
  • ALogP: -0.54
  • ChEMBL Molecule:
    alovudine  
More Chemistry

Pharmacology

Alternative names

1-(3'-fluoro-3'-deoxy-beta-d-erythropentofuranosyl)thymine | (18f)3'-deoxy-3'-fluorothymidine | (18f)flt | 18f flt | 18f-flt | (18)flt cpd | 3'-deoxy-3'-(18f)fluorothymidine | 3'-deoxy-3'-fluorothymidine | 3'-(f-18)fluoro-3'-deoxythymidine | 3'-fluoro-2',3'-dideoxythymidine | 3'-fluoro-3'-deoxythymidine | 3'-fluorothymidine | alovudine | cl-184824 | fddt

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2/Phase 3)

HIV Infections (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Lymphoma (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Rectal Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue